ERBB2 and neoplasm: The antibody directed the effects of the sialidase to the HER2-expressing tumor cells, simultaneously reducing Siglec-mediated NK cell suppression and exposing the tumor cells to NK cell-mediated antibody-dependent cytotoxicity.